세계의 장질환 검사 시장 보고서 : 제품 유형, 방법, 질병 유형, 최종 사용자 및 지역별(2024-2032년)

The global enteric disease testing market size reached US$ 4.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 3.1% during 2024-2032. The rising incidences of gastrointestinal infections, increasing awareness about the early detection, advancements in diagnostic technologies, the growing demand for rapid and accurate testing methods, and rising global focus on food and water safety standards are some of the factors propelling the growth of the market.

Enteric Disease Testing Market Analysis:

Major Market Drivers: The rising prevalence of gastrointestinal infections across the globe represents the major driver of the market. Factors including poor sanitation, contaminated water, and foodborne pathogens contribute to the increasing incidence of enteric diseases. Significant advancements in diagnostic technologies offering rapid and accurate results further driving the market growth.

Key Market Trends: The widespread adoption of molecular diagnostics represents the key trends in the market. Techniques including polymerase chain reaction (PCR) and next-generation sequencing (NGS) are gaining popularity due to their high sensitivity, specificity, and rapid turnaround time. These advanced diagnostic methods enable the detection of a wide range of pathogens, contributing to more accurate and comprehensive testing.

Geographical Trends: Asia Pacific accounts for the largest region in the enteric disease testing market growth. The high incidence of gastrointestinal infections is driving the market growth across the region due to poor sanitation, increasing healthcare awareness, government initiatives for disease control, and advancements in diagnostic technologies.

Competitive Landscape: Some of the major market players in the enteric disease testing industry include Abbott Laboratories, BD (Becton, Dickinson and Company), Bio-Rad Laboratories Inc., Biomerica Inc., Biomerieux SA, Cepheid Inc. (Danaher Corporation), Coris BioConcept, DiaSorin, Meridian Bioscience Inc. and Quest Diagnostics, among many others.

Challenges and Opportunities: The market faces various challenges including limited access to advanced diagnostic facilities in remote and low-income regions, which hampers timely disease detection. However, the market also faces several opportunities such as advancements in molecular diagnostics and point-of-care testing which offer rapid and accurate results.

Enteric Disease Testing Market Trends:

Rising Incidence of Gastrointestinal Infections

The growing prevalence of enteric diseases due to poor sanitation, contaminated food and water, and high population density, especially in developing regions, is driving the demand for effective diagnostic testing. According to an article published by the Times of India in 2024, Bengaluru witnesses a rise in gastrointestinal infections attributed to contaminated water sources and poor sanitation. Children are at risk of dehydration due to diarrhea, emphasizing the importance of ORS and avoiding milk during infections. According to the WHO, approximately 1.5 million people worldwide die of diarrheal disease alone. Children under the age of 5 living in developing countries are particularly affected by conditions such as diarrhea and vomiting through malnutrition and death. This is further boosting the enteric disease testing market value significantly.

Growing Government Initiatives and Regulations

The rising government and health organizations are implementing strict food and water safety standards and investing in public health infrastructure. This further increases the need for regular and reliable enteric disease testing to prevent outbreaks and ensure public safety which is further contributing to the growth of the market. For instance, in April 2024, The Food Safety and Standards Authority of India (FSSAI) launched an extensive awareness and sensitization program targeting major markets in the national capital, in collaboration with the Food Safety Department, Delhi. Similarly, the National Health Mission (NHM), a key program under the Modi government, focuses on improving healthcare infrastructure, providing essential drugs and diagnostics, and strengthening human resource capabilities at the grassroots level. These initiatives are aimed at reducing the need for patients to seek expensive treatments outside their localities which is further boosting the enteric disease testing market forecast over the coming years.

Significant Advancements in Diagnostic Technologies

The increasing innovation in molecular diagnostics including polymerase chain reaction (PCR) and next-generation sequencing (NGS), provide rapid, accurate, and comprehensive detection of enteric pathogens, which is boosting the market growth. For instance, in August 2023, ArcticZymes Technologies (AZT) announced the launch of its new product, AZtaq(TM) DNA Polymerase. AZtaq(TM) is a high-quality thermostable DNA polymerase suitable for use in polymerase chain reaction (PCR) applications. Launched the AZtaq(TM) is a natural expansion of the Company's molecular tools portfolio. Being an essential enzyme in PCR, the thermostable DNA polymerase plays a pivotal role and enables numerous applications within molecular diagnostics and research. This is further driving the enteric disease testing market revenue across the globe.

Enteric Disease Testing Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, technique, disease type, and end user.

Breakup by Product Type:

Reagents and Consumables

Equipment

The report has provided a detailed breakup and analysis of the market based on the product type. This includes reagents and consumables, and equipment.

The demand for reagents and consumables in the market is driven by the need for accurate and efficient diagnostic processes. Frequent testing for gastrointestinal pathogens requires a constant supply of high-quality reagents and consumables. Additionally, the rise in infectious disease prevalence, coupled with advancements in molecular and rapid testing methods, necessitates the use of specialized consumables. Increased government funding and healthcare infrastructure development further boost demand for these essential testing components.

Technological advancements in diagnostic machinery, such as automated PCR systems and next-generation sequencing platforms are further driving the demand for equipment in the enteric disease testing market report. The need for high-throughput, reliable, and precise diagnostic tools drive the adoption of advanced equipment. Expanding healthcare infrastructure, particularly in emerging markets, and increased investment in laboratory modernization also contribute to the growing demand. Enhanced disease surveillance programs and public health initiatives further stimulate the market for diagnostic equipment.

Breakup by Technique:

Molecular Diagnostics

Immunodiagnostics

Molecular diagnostics holds the largest share of the industry

A detailed breakup and analysis of the market based on the technique have also been provided in the report. This includes molecular diagnostics and immunodiagnostics. According to the report, molecular diagnostics accounted for the largest enteric disease testing market share.

The demand for molecular diagnostics techniques in the market is driven by their high accuracy, sensitivity, and rapid turnaround times. These techniques, such as PCR and next-generation sequencing, enable precise identification of a wide range of pathogens, improving disease management and outbreak control. For instance, in November 2023, Roche announced the launch of the LightCycler(R) PRO System based on the proven gold standard technology of the LightCycler(R) Systems that came before it. This new system raises the bar for performance and usability while bridging the gap between translational research and in vitro diagnostics. The LightCycler PRO System further complements Roche's molecular PCR testing portfolio, which includes solutions for a variety of healthcare professionals - from those performing research to those testing patients for cancer, infectious diseases, and other public health challenges. This is further driving the enteric disease testing demand across the globe.

Breakup by Disease Type:

Bacterial Enteric Disease

C. Difficile

Campylobacteriosis

Cholera

E. Coli

H. Pylori

Salmonellosis

Shigellosis

Viral Enteric Disease

Rotavirus

Norovirus

Others

Parasitic Enteric Disease

Amebiasis

Cryptosporidiosis

Giardiasis

Bacterial enteric disease holds the largest share of the industry

The report has provided a detailed breakup and analysis of the market based on the disease type. This includes Bacterial Enteric Disease (C. Difficile, Campylobacteriosis, Cholera, E. Coli, H. Pylori, Salmonellosis, and Shigellosis), Viral Enteric Disease (Rotavirus, Norovirus, and Others), and Parasitic Enteric Disease (Amebiasis, Cryptosporidiosis, and Giardiasis). According to the report, Bacterial Enteric Disease accounted for the largest market share.

The demand for enteric disease testing in bacterial types is driven by the high prevalence of infections like C. difficile, E. coli, and Salmonellosis, which pose significant public health risks. Rapid, accurate diagnostics are crucial for effective treatment, outbreak management, and infection control. The association of H. pylori with severe gastrointestinal conditions also fuels testing demand. Increasing foodborne and waterborne outbreaks, stringent food safety regulations, and the need for efficient healthcare interventions further boost the market for bacterial enteric disease testing.

Breakup by End User:

Hospital Diagnostic Laboratories

Independent Diagnostic Laboratories

Academic and Research Institutes

Others

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospital diagnostic laboratories, independent diagnostic laboratories, academic and research institutes, and others.

In hospital diagnostic laboratories, the demand for enteric disease testing is driven by the necessity for prompt and accurate diagnosis to ensure effective patient management and treatment. High patient volumes and the critical nature of diagnosing gastrointestinal infections necessitate reliable and efficient testing protocols.

Independent diagnostic laboratories see demand due to their specialized services and ability to provide rapid, high-volume testing. They play a crucial role in routine screening, outbreak management, and offering advanced diagnostic techniques, meeting the needs of both healthcare providers and patients. This is further creating a positive enteric disease testing market outlook.

In academic and research institutes, demand is driven by the focus on studying enteric pathogens, developing innovative diagnostic methods, and conducting epidemiological research. Increased funding and grants for infectious disease research enhance the need for comprehensive and precise testing capabilities, supporting scientific advancements and public health initiatives.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Asia Pacific leads the market, accounting for the largest enteric disease testing market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific represents the largest market for enteric disease testing.

The market for enteric disease testing in Asia Pacific is driven by the increasing incidence rates of gastrointestinal infections due to poor sanitation and hygiene. Recent data from the Global Enteric Multicenter Study (GEMS) on the burden and etiology of diarrhea among children residing in developing countries showed that rotavirus, Cryptosporidium spp., enterotoxigenic Escherichia coli (ETEC), and Shigella spp. are the major causes of diarrheal diseases and death. Furthermore, norovirus infections are the principal cause of foodborne disease outbreaks and are associated with approximately 20% of diarrhea cases, with similar prevalence in both children and adults. Consequently, the growing awareness of health issues, increased government initiatives for disease control, and improvements in healthcare infrastructure also boost demand. Advancements in diagnostic technologies and the rising prevalence of food and waterborne diseases further propel the market growth. Rapid urbanization and the expanding middle class population base, with greater access to healthcare, are contributing to the market growth.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the enteric disease testing industry include Abbott Laboratories, BD (Becton, Dickinson and Company), Bio-Rad Laboratories Inc., Biomerica Inc., Biomerieux SA, Cepheid Inc. (Danaher Corporation), Coris BioConcept, DiaSorin, Meridian Bioscience Inc. and Quest Diagnostics.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The competitive landscape of the enteric disease testing market is highly competitive with key players such as Abbott Laboratories, Thermo Fisher Scientific, Bio-Rad Laboratories, and Becton, Dickinson and Company. These players focus on developing advanced diagnostic technologies, including molecular diagnostics and rapid testing kits, to enhance detection accuracy and speed. For instance, in July 2023, Thermo Fisher Scientific introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results to address challenges with error-prone, manual molecular testing workflows. By connecting workflow steps within one interface, Diomni Enterprise can increase a lab's ability to dynamically respond to today's rapidly changing testing environment.

Enteric Disease Testing Market News:

In March 2023, Biomerica, Inc. announced the launch of its InFoods(R) IBS test. The test is being performed in a CLIA-certified, and CAP-accredited high-complexity laboratory facility and offered as a laboratory-developed test (LDT). The Company further announced all validation testing necessary for the InFoods IBS product to be offered as an LDT has been completed. The first patient samples have been processed.

In October 2022, Thermo Fisher Scientific, the world leader in the field of science, announced the launch of the TaqPath Enteric Bacterial Select Panel, a CE-IVD marked panel designed to detect common gastrointestinal (GI) bacteria and help enable clinicians to identify the root cause of an infection and administer the most appropriate treatment to their patients more quickly. The panel was validated and registered under IVDD in May 2022.

Key Questions Answered in This Report:

• How has the global enteric disease testing market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global enteric disease testing market?
• What is the impact of each driver, restraint, and opportunity on the global enteric disease testing market?
• What are the key regional markets?
• Which countries represent the most attractive enteric disease testing market?
• What is the breakup of the market based on the product type?
• Which is the most attractive product type in the enteric disease testing market?
• What is the breakup of the market based on the technique?
• Which is the most attractive technique in the enteric disease testing market?
• What is the breakup of the market based on the disease type?
• Which is the most attractive disease type in the enteric disease testing market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the enteric disease testing market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global enteric disease testing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Enteric Disease Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Reagents and Consumables
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Equipment
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technique

• 7.1 Molecular Diagnostics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Immunodiagnostics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Disease Type

• 8.1 Bacterial Enteric Disease
  • 8.1.1 Market Trends
  • 8.1.2 Major Types
    • 8.1.2.1 C. Difficile
    • 8.1.2.2 Campylobacteriosis
    • 8.1.2.3 Cholera
    • 8.1.2.4 E. Coli
    • 8.1.2.5 H. Pylori
    • 8.1.2.6 Salmonellosis
    • 8.1.2.7 Shigellosis
  • 8.1.3 Market Forecast
• 8.2 Viral Enteric Disease
  • 8.2.1 Market Trends
  • 8.2.2 Major Types
    • 8.2.2.1 Rotavirus
    • 8.2.2.2 Norovirus
    • 8.2.2.3 Others
  • 8.2.3 Market Forecast
• 8.3 Parasitic Enteric Disease
  • 8.3.1 Market Trends
  • 8.3.2 Major Types
    • 8.3.2.1 Amebiasis
    • 8.3.2.2 Cryptosporidiosis
    • 8.3.2.3 Giardiasis
  • 8.3.3 Market Forecast

9 Market Breakup by End User

• 9.1 Hospital Diagnostic Laboratories
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Independent Diagnostic Laboratories
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Academic and Research Institutes
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 BD (Becton, Dickinson and Company)
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Bio-Rad Laboratories Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Biomerica Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Biomerieux SA
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Cepheid Inc. (Danaher Corporation)
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 SWOT Analysis
  • 15.3.7 Coris BioConcept
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 DiaSorin
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Meridian Bioscience Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Quest Diagnostics
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis